اثر تمرین هوازی تداومی و تناوبی همراه با مصرف مکمل سیلیمارین بر میزان آنزیم‌های کبدی و تغییرات بافت کبد در موش‌های صحرایی مبتلا به کبد چرب غیر الکلی القاء شده با دگزامتازون

1. 1. Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Progress in lipid research. 2009;48(1):1-26.
2. 2. Demir M, Lang S, Steffen HM. Nonalcoholic fatty liver disease–current status and future directions. Journal of digestive diseases. 2015;16(10):541-57.
3. 3. Ahmed MB, Hasona NA-S, Selemain HA-H. Protective effects of extract from dates (Phoenix dactylifera L.) and ascorbic acid on thioacetamide-induced hepatotoxicity in rats. Iranian Journal of Pharmaceutical Research. 2008; 7(3): 193-201.
4. 4. Yu J, Marsh S, Hu J, Feng W, Wu C. The pathogenesis of nonalcoholic fatty liver disease: interplay between diet, gut microbiota, and genetic background. Gastroenterology research and practice. 2016;. 2016:2862173.
5. Sullivan S, Kirk EP, Mittendorfer B, Patterson BW, Klein S. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology. 2012;55(6):1738-45.
6. Johnson NA, Sachinwalla T, Walton DW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009; 50:1105–12.
7. Cassidy S, Thoma C, Houghton D, et al. High-intensity interval training: a review of its impact on glucose control and cardiometabolic health. Diabetologia 2017;60:7–23.
8. Abdelbasset WK, Tantawy SA, Kamel DM, et al. A randomized controlled trial on the effectiveness of 8-week high-intensity interval exercise on intrahepatic triglycerides, visceral lipids, and health-related quality of life in diabetic obese patients with nonalcoholic fatty liver disease. Medicine 2018;98:e14918.
9. Sahin E, Bagci R, Bektur Aykanat NE, Kacar S, and Sahinturk V. Silymarin attenuated nonalcoholic fatty liver disease through the regulation of endoplasmic reticulum stress proteins GRP78 and XBP‐1 in mice. Journal of food biochemistry. 2020; 44(6):e13194.
10. Tamayo C, Diamond S. Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.). Integrative cancer therapies. 2007;6(2):146-57.
11. Shaker E, Mahmoud H, Mnaa S. Silymarin, the antioxidant component and Silybum marianum extracts prevent liver damage. Food and Chemical Toxicology. 2010;48(3):803-6.
12. Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. The American journal of medicine. 2002;113(6):506-15.

13. Federico A, Dallio M, Masarone M, Gravina AG, Di Sarno R, Tuccillo C, Cossiga V, Lama S, Stiuso P, Morisco F, Persico M, Loguercio C. Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients. Oxid Med Cell Longev. 2019:8742075.
14. Zhong, S.; Fan, Y. The therapeutic e_ect of silymarin in the treatment of nonalcoholic fatty disease A meta-analysis (PRISMA) of randomized control trials. Medicine 2017, 96, e9061.
15. Curcio A, Romano A, Cuozzo S, et al. Silymarin in Combination with Vitamin C, Vitamin E, Coenzyme Q10 and Selenomethionine to Improve Liver Enzymes and Blood Lipid Profile in NAFLD Patients. Medicina (Kaunas). 2020;56(10):544.
16. Guo R, Liong EC, So KF, Fung M-L, Tipoe GL. Beneficial mechanisms of aerobic exercise on hepatic lipid metabolism in non-alcoholic fatty liver disease. Hepatobiliary & Pancreatic Diseases International. 2015;14(2):139-44.
17. Suzuki A, Lindor K, St Saver J, Lymp J, Mendes F, Muto A, et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. Journal of hepatology. 2005; 43(6):1060-6.
18. Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011;60(9):1278-83.
19. Ghalandari K, Shabani M, Khajehlandi A, Mohammadi A. Effect of aerobic training with silymarin consumption on glycemic indices and liver enzymes in men with type 2 diabetes. Arch Physiol Biochem. 2020;1-6.
20. Safaeian L, Zolfaghari B, Karimi S, Talebi A, Ghazvini MA. The effects of hydroalcoholic extract of Allium elburzense Wendelbo bulb on dexamethasone-induced dyslipidemia, hyperglycemia, and oxidative stress in rats. Research in pharmaceutical sciences. 2018;13(1):22.
21. Prakash P, Singh V, Jain M, Rana M, Khanna V, Barthwal MK, et al. Silymarin ameliorates fructose induced insulin resistance syndrome by reducing de novo hepatic lipogenesis in the rat. European journal of pharmacology. 2014; 727:15-28
22. Kolahdouzi S, Talebi-Garakani E, Hamidian G, Safarzade A. Exercise training prevents high-fat diet-induced adipose tissue remodeling by promoting capillary density and macrophage polarization. Life sciences. 2019;220:32-43.
23. Jackson ER, Kilroy C, Joslin DL, Schomaker SJ, Pruimboom-Brees I, Amacher DE. The early effects of short-term dexamethasone administration on hepatic and serum alanine aminotransferase in the rat. Drug and chemical toxicology. 2008;31(4):427-45.
24. Nkono B, Sokeng SD, Désiré DDP, Kamtchouing P. Antihyperglycemic and antioxydant properties of alstonia boonei De wild.(Apocynaceae) stem bark aqueous extract in dexamethasone-induced hyperglycemic rats. Int J Diabetes Res. 2014;3(3):27-35.
25. Tovchiga OV. The influence of goutweed (Aegopodium podagraria L.) tincture and metformin on the carbohydrate and lipid metabolism in dexamethasone-treated rats. BMC complementary and alternative medicine 2016; 16, 235.
26. Almeida M, Han L, Ambrogini E, Weinstein RS, Manolagas SC. Glucocorticoids and tumor necrosis factor α increase oxidative stress and suppress Wnt protein signaling in osteoblasts. Journal of Biological Chemistry. 2011;286(52):44326-35.
27. Zhen Yf, Wang Gd, Zhu Lq, Tan Sp, Zhang Fy, Zhou Xz, et al. P53 dependent mitochondrial permeability transition pore opening is required for dexamethasone‐induced death of osteoblasts. Journal of cellular physiology. 2014;229(10):1475-83.
28. Guo, Y., Wang, S., Wang, Y., & Zhu, T. (2016). Silymarin improved diet-induced liver damage and insulin resistance by decreasing inflammation in mice. Pharmaceutical biology, 54(12), 2995–3000.
29. Shelbaya L. Evaluation of protective and antioxidant activity of milk thistle on paracetamol-induced toxicity in rats. The Journal of American Science. 2013;9(10):272-8.
30. Pradhan S, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian journal of medical research. 2006;124 (5): 491-504
31. Mahjoor A, Dehghan A. Effect of silymarin on metabolic factors of food-restricted over conditioned Wistar rats. Pakistan journal of biological sciences: PJBS. 2008;11(14):1835-9.
32. Zhang W, Hong R, Tian T. Silymarin’s protective effects and possible mechanisms on alcoholic fatty liver for rats. Biomolecules & therapeutics. 2013;21(4):264.
33. Rodriguez B, Torres DM, Harrison SA. Physical activity: an essential component of lifestyle modification in NAFLD. Nature reviews Gastroenterology & hepatology. 2012; 9(12):726-31.
34. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288:E462e8.
35. Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48:792e8.
36. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37:1286e92.
37. Linden, M.A.; Fletcher, J.A.; Morris, E.M.; Meers, G.M.; Laughlin, M.H.; Booth, F.W.; Sowers, J.R.; Ibdah, J.A.;Thyfault, J.P.; Rector, R.S. Treating NAFLD in OLETF rats with vigorous-intensity interval exercise training.Med. Sci. Sports Exerc. 2015, 47, 556–567.
38. Kapravelou, G.; Martínez, R.; Andrade, A.M.; Nebot, E.; Camiletti-Moirón, D.; Aparicio, V.A.;Lopez-Jurado, M.; Aranda, P.; Arrebola, F.; Fernandez-Segura, E.; et al. Aerobic interval exercise improvesparameters of nonalcoholic fatty liver disease (NAFLD) and other alterations of metabolic syndrome in obese Zucker rats. Appl. Physiol. Nutr. Metab. 2015, 40, 1242–1252.

39. Marcinko, K.; Sikkema, S.R.; Samaan, M.C.; Kemp, B.E.; Fullerton, M.D.; Steinberg, G.R. High intensityinterval training improves liver and adipose tissue insulin sensitivity. Mol. Metab. 2015, 4, 903–915.
40. Kalaki-Jouybari, F.; Shanaki, M.; Delfan, M.; Gorgani-Firouzjae, S.; Khakdan, S. High-intensity intervaltraining (HIIT) alleviated NAFLD feature via miR-122 induction in liver of high-fat high-fructose dietinduced diabetic rats. Archives of physiology and biochemistry. 2020, 126(3), 242–249.
41. Cho J, Kim S, Lee S, Kang H. Effect of Training Intensity on Nonalcoholic Fatty Liver Disease. Medicine and science in sports and exercise. 2015; 47(8):1624-1634.
42. Nicastro H, Zanchi NE, da Luz CR, et al. Effects of leucine supplementation and resistance exercise on dexamethasone-induced muscle atrophy and insulin resistance in rats. Nutrition. 2012; 28(4):465-471.

43. Pettersson J, Hindorf U, Persson P, et al. Muscular exercise can cause highly pathological liver function tests in healthy men. Br J Clin Pharmacol. 2008; 65(2):253-259.